Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.77 |
| ▸ | TK1 | P04183 | 2/20 | 0.58 |
| ▸ | TK2 | O00142 | 4/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.52 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29725104 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL2579194 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL654674 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL3412420 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL12315567 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL97336 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL97335 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL2056540 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL3389861 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 | |
| SCHEMBL2056544 | 0.88 | PYGM (0.97) | PYGMTK1TK2P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | GILEAD PHARMASSET LLC (US) | 2018-10-16 | — | — | US | disclosed |
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | GILEAD SCIENCES, INC. (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PHARMASSET, INC. | 2011-11-03 | — | — | US | disclosed |
| EP-2251015-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | Pharmasset, Inc. (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | PHARMASSET, INC. | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057863-A1 | MODIFIED NUCLEOSIDES FOR THE TREATMENT OF VIRAL INFECTIONS AND ABNORMAL CELLULAR PROLIFERATION | SLC29A1, PNP, SLC29A2 | PYGM 89/4885TK1 12/4885TK2 149/4885 |
| US-20110269707-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation | PNP, ALPP, XDH | PYGM 4/4885TK1 35/4885TK2 261/4885 |
| US-10100076-B2 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, SLC29A2, PNP | PYGM 99/4885TK1 5/4885TK2 159/4885 |
| US-20030087873-A1 | Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation | SLC29A1, PNP, SLC29A2 | PYGM 72/4885TK1 12/4885TK2 190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.